TNSN01142A1 - Association de nif et d'un agent neuroprotecteur ou thrombolytique-fibrinolytique, et procede pour leur preparation - Google Patents

Association de nif et d'un agent neuroprotecteur ou thrombolytique-fibrinolytique, et procede pour leur preparation

Info

Publication number
TNSN01142A1
TNSN01142A1 TNTNSN01142A TNSN01142A TNSN01142A1 TN SN01142 A1 TNSN01142 A1 TN SN01142A1 TN TNSN01142 A TNTNSN01142 A TN TNSN01142A TN SN01142 A TNSN01142 A TN SN01142A TN SN01142 A1 TNSN01142 A1 TN SN01142A1
Authority
TN
Tunisia
Prior art keywords
nif
thrombolytic
neuroprotective
preparation
association
Prior art date
Application number
TNTNSN01142A
Other languages
English (en)
Inventor
John Brearley Christopher
Butler Paul
Babubhai Chahwala Suresh
Chopp Michael
Krams Michael
Looby Michael
Macintyre Fiona
Brian Mcelroy Andrew
Dorothy Mcharg Aileen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN01142A1 publication Critical patent/TNSN01142A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION COMPRENANT AU MOINS UN FACTEUR D'INHIBITION DES CELLULES NEUTROPHILES (NIF) ET AU MOINS UN AUTRE AGENT NEUROPROTECTEUR OU THROMBOLYTIQUE / FIBRINOLYTIQUE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES. ELLE CONCERNE EGALEMENT UN PROCEDE POUR SA PREPARATION. APPLICATION : UTILISATION DE CETTE COMPOSITION DANS LE TRAITEMENT D'ETATS PHYSIOPATHOLOGIQUES IMPLIQUANT LES CELLULES NEUTROPHILES.
TNTNSN01142A 2000-10-17 2001-10-16 Association de nif et d'un agent neuroprotecteur ou thrombolytique-fibrinolytique, et procede pour leur preparation TNSN01142A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0025473.0A GB0025473D0 (en) 2000-10-17 2000-10-17 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
TNSN01142A1 true TNSN01142A1 (fr) 2005-11-10

Family

ID=9901490

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01142A TNSN01142A1 (fr) 2000-10-17 2001-10-16 Association de nif et d'un agent neuroprotecteur ou thrombolytique-fibrinolytique, et procede pour leur preparation

Country Status (13)

Country Link
US (1) US20020098179A1 (fr)
AP (1) AP2001002295A0 (fr)
AR (1) AR034698A1 (fr)
AU (1) AU2002210795A1 (fr)
DO (1) DOP2001000266A (fr)
GB (1) GB0025473D0 (fr)
GT (1) GT200100207A (fr)
HN (1) HN2001000232A (fr)
PA (1) PA8530701A1 (fr)
PE (1) PE20020536A1 (fr)
TN (1) TNSN01142A1 (fr)
UY (1) UY26969A1 (fr)
WO (1) WO2002032446A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20030219431A1 (en) * 2002-05-24 2003-11-27 Empire Pharmaceuticals, Inc. Treatment of neuronal and neurological damage associated with spinal cord injury
CN1310949C (zh) * 2003-01-13 2007-04-18 重庆富进生物医药有限公司 具有抑制白细胞功能和凝血酶活性的双功能嵌合蛋白
CA2426115A1 (fr) * 2003-04-18 2004-10-18 Victor Gurewich Methodes, dispositifs et compositions pour la lyse des caillots sanguins occlusifs tout en protegeant les caillots qui obturent les blessures
JP2008510835A (ja) * 2004-08-25 2008-04-10 エッセンシャリス，インク． カリウムａｔｐチャンネル開放因子の製剤処方、及びその使用
US20070167419A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
WO2006094120A2 (fr) * 2005-03-02 2006-09-08 The Regents Of The University Of California Traitement d'une embolie cerebro-vasculaire
PL1968601T3 (pl) 2006-01-05 2012-03-30 Essentialis Inc Sole związków otwierających kanały potasowe ATP i ich zastosowanie
CN101245110B (zh) * 2007-02-16 2010-09-15 鲁南制药集团股份有限公司 重组中性粒细胞抑制因子和水蛭原嵌合蛋白及其药物组合物
AU2008272923A1 (en) * 2007-07-02 2009-01-08 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
TWI482628B (zh) * 2007-10-18 2015-05-01 Lundbeck & Co As H 新穎之血栓溶解病患次群
JP6005514B2 (ja) 2009-06-10 2016-10-12 ノノ インコーポレイテッド 神経疾患の治療のためのモデル系及び治療計画
KR102425466B1 (ko) * 2011-06-24 2022-07-25 노노 인코포레이티드 허혈에 대한 psd-95 억제제와의 조합 요법
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
CA2966332C (fr) 2014-11-03 2024-04-16 Thrombolytic Science, Llc Methodes et compositions pour thrombolyse sure et efficace
US10336827B2 (en) 2015-10-29 2019-07-02 Wayne State University Compositions and methods to treat solid tumors
WO2018232305A1 (fr) 2017-06-16 2018-12-20 Thrombolytic Science, Llc Procédés et compositions pour la thrombolyse
EP4248954A4 (fr) * 2020-11-17 2024-06-26 Talengen International Limited Procédé et médicament pour augmenter le taux de bdnf
AU2022289008A1 (en) * 2021-06-09 2023-12-21 Proniras Corporation Methods of treating or preventing conditions associated with opiate withdrawal or opiate relapse

Also Published As

Publication number Publication date
PA8530701A1 (es) 2003-06-30
HN2001000232A (es) 2002-04-22
WO2002032446A3 (fr) 2002-07-11
PE20020536A1 (es) 2002-06-20
DOP2001000266A (es) 2002-05-31
US20020098179A1 (en) 2002-07-25
AR034698A1 (es) 2004-03-17
AU2002210795A1 (en) 2002-04-29
GT200100207A (es) 2002-08-19
GB0025473D0 (en) 2000-11-29
AP2001002295A0 (en) 2001-12-31
UY26969A1 (es) 2002-06-20
WO2002032446A2 (fr) 2002-04-25

Similar Documents

Publication Publication Date Title
TNSN01142A1 (fr) Association de nif et d'un agent neuroprotecteur ou thrombolytique-fibrinolytique, et procede pour leur preparation
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00028A1 (fr) Derives de quinoleine -2-one a substituant heteroaryle nouveaux procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01017A1 (fr) Compositions comprenant un antibiotique azalide, et procedes pour leur preparation
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26914A1 (fr) Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale
MY122312A (en) Use of a copolymer having a surfactant or tensio- active structure as dispersing agent and/or grinding agent
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
HUP0004348A2 (hu) Vegyületek női szexuális diszfunkció kezelésére
PL361341A1 (en) Novel pharmaceutical composition
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN00065A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant.
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99203A1 (fr) Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation
AU2001292843A1 (en) Crystal structure of bace and uses thereof
MA28583B1 (fr) Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale
TNSN99007A1 (fr) Composition de mesylate de trovafloxacine et procede pour sa preparation
HK1041449B (zh) 可在體內減少α2-抗纖溶酶的化合物在製備用於治療局部缺血性中風的組合物中的用途
TNSN00112A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
AU6682594A (en) Treatment of septic shock
CA2224413A1 (fr) Immunovecteurs utilisables pour le transport intracellulaire et intranucleaire
TNSN00106A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation